Packaging


Labelling for life We don’t often think of labelling as a risky behaviour, but incorrect information can be detrimental


at every stage of the clinical trial supply chain, not to mention for patients once a product reaches its intended recipient. These risks are further intensified when it comes to cell and gene therapies, which often have strict specifications, like temperature control, that must be made clear on any packaging. Kim Thomas speaks to Zbigniew Szczepiorkowski, professor of pathology and laboratory medicine at Dartmouth College, to find out how the evolution of a standardised labelling system has been essential to ensuring the safety of subjects in clinical trials.


orrect labelling saves lives. That might sound strange given the huge range of labelled products that pose no risk, but in the field of medicine, even a slight mistake in drug dosage can be fatal. The same is true for medical products of human origin (MPHOs), in which biological material from a donor or a patient’s own body is used to create a


C 36


therapeutic. Unsurprisingly, the most common MPHO is blood. Globally, 118.5 million blood donations are collected every year, and, as Zbigniew Szczepiorkowski, professor of pathology and laboratory medicine at Dartmouth College and chair of the International Council for Commonality in Blood Banking Automation (ICCBBA), points out, 10% of


Clinical Trials Insight / www.worldpharmaceuticals.net


JulsIst/Shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41